| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAT1 |
| Uniprot No | Q96RN1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-970aa |
| 氨基酸序列 | MAQLERSAISGFSSKSRRNSFAYDVKREVYNEETFQQEHKRKASSSGNMNINITTFRHHVQCRCSWHRFLRCVLTIFPFLEWMCMYRLKDWLLGDLLAGISVGLVQVPQGLTLSLLARQLIPPLNIAYAAFCSSVIYVIFGSCHQMSIGSFFLVSALLINVLKVSPFNNGQLVMGSFVKNEFSAPSYLMGYNKSLSVVATTTFLTGIIQLIMGVLGLGFIATYLPESAMSAYLAAVALHIMLSQLTFIFGIMISFHAGPISFFYDIINYCVALPKANSTSILVFLTVVVALRINKCIRISFNQYPIEFPMELFLIIGFTVIANKISMATETSQTLIDMIPYSFLLPVTPDFSLLPKIILQAFSLSLVSSFLLIFLGKKIASLHNYSVNSNQDLIAIGLCNVVSSFFRSCVFTGAIARTIIQDKSGGRQQFASLVGAGVMLLLMVKMGHFFYTLPNAVLAGIILSNVIPYLETISNLPSLWRQDQYDCALWMMTFSSSIFLGLDIGLIISVVSAFFITTVRSHRAKILLLGQIPNTNIYRSINDYREIITIPGVKIFQCCSSITFVNVYYLKHKLLKEVDMVKVPLKEEEIFSLFNSSDTNLQGGKICRCFCNCDDLEPLPRILYTERFENKLDPEASSINLIHCSHFESMNTSQTASEDQVPYTVSSVSQKNQGQQYEEVEEVWLPNNSSRNSSPGLPDVAESQGRRSLIPYSDASLLPSVHTIILDFSMVHYVDSRGLVVLRQICNAFQNANILILIAGCHSSIVRAFERNDFFDAGITKTQLFLSVHDAVLFALSRKVIGSSELSIDESETVIRETYSETDKNDNSRYKMSSSFLGSQKNVSPGFIKIQQPVEEESELDLELESEQEAGLGLDLDLDRELEPEMEPKAETETKTQTEMEPQPETEPEMEPNPKSRPRAHTFPQQRYWPMYHPSMASTQSQTQTRTWSVERRRHPMDSYSPEGNSNEDV |
| 预测分子量 | 109 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于TAT1重组蛋白的模拟参考文献示例，供参考：
---
1. **标题**：*Prokaryotic Expression and Purification of TAT1 Recombinant Protein for Cell-Penetrating Studies*
**作者**：Smith J, Lee R, et al.
**摘要**：本研究利用大肠杆菌系统成功表达并纯化TAT1重组蛋白，通过优化诱导条件提高可溶性蛋白产量，并验证其穿透细胞膜的能力，为后续药物递送应用奠定基础。
2. **标题**：*TAT1-Fused Nanoparticles Enhance Targeted Delivery of Anticancer Drugs in vitro*
**作者**：Chen L, Wang X, et al.
**摘要**：将TAT1重组蛋白与载药纳米颗粒结合，显著提高了肿瘤细胞对化疗药物的摄取效率，体外实验显示其对乳腺癌细胞的靶向性和细胞毒性增强，提示其在癌症治疗中的潜力。
3. **标题**：*Structural and Functional Analysis of TAT1 Recombinant Protein in Blood-Brain Barrier Penetration*
**作者**：Garcia M, Patel S, et al.
**摘要**：通过定点突变和体外血脑屏障模型，揭示了TAT1重组蛋白中关键氨基酸残基对其跨膜转运效率的影响，为神经退行性疾病药物的脑部递送提供理论支持。
---
注：以上文献为模拟示例，实际研究需检索PubMed、Google Scholar等数据库获取真实信息。
**Background of TAT1 Recombinant Protein**
TAT1 recombinant protein is derived from the HIV-1 trans-activator of transcription (TAT) protein, a viral regulatory protein critical for viral replication. The TAT protein is known for its unique cell-penetrating ability, mediated by its basic domain (amino acids 47–57), which enables it to traverse cell membranes efficiently. This property has been harnessed in biotechnology to create TAT-based fusion proteins, including TAT1. designed to deliver therapeutic molecules or tags into cells.
Recombinant TAT1 is typically engineered using genetic recombination techniques, where the TAT peptide sequence is fused to a target protein or functional domain. The chimeric protein retains the membrane-penetrating capability of TAT while conferring additional biological activities, such as enzyme function, signaling modulation, or diagnostic labeling. TAT1 is commonly produced in bacterial or mammalian expression systems, followed by purification via affinity chromatography.
In research and therapeutics, TAT1 has been utilized for intracellular delivery of proteins, nucleic acids, and nanoparticles, overcoming limitations of traditional transfection methods. Its applications span cancer therapy (e.g., delivering pro-apoptotic proteins), neurodegenerative disease studies (e.g., crossing the blood-brain barrier), and vaccine development (e.g., antigen delivery). However, challenges remain, including potential immunogenicity, off-target effects, and variable efficiency across cell types.
Recent advancements focus on optimizing TAT1’s structure to enhance specificity and reduce toxicity, such as incorporating cell-specific targeting motifs or stimuli-responsive elements. These innovations aim to expand its utility in precision medicine and drug delivery systems.
×
